Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Science of eradication
Products for vulnerable populations
Working with regulators
Information for scientists
Call for proposals
TPPs & TCPs
Project of the year award
Computational chemistry
Global health compound design webinars
R&D challenges
Access
Products & projects
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Product maps
ASAQ Winthrop® map
ASMQ map
Artesun® map
Coartem®
Dispersible
map
Eurartesim® map
Kozenis/Krintafel
map
Pyramax® map
Pyramax® granules map
Rectal artesunate map
SPAQ map
Tool Kits
Injectable artesunate tool kit
Rectal artesunate tool kit
Seasonal Malaria Chemoprevention Tool Kit
The road to health impact
Access challenges
Partnering
Our partner network
The PDP model
Socially responsible agreements
Our clinical centre partners
Our donors
Current donors
Past donors
Donate to MMV
Donor stories
Our impact
Achievements
Real life stories
Impact of the global malaria community
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff map
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
MMV's internship programme
Policies
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Optimizing artemisinin production
Malaria online course
Newsroom
News & Press Releases
Films
Infographics
Interviews
Image slideshows
Publications
Audio
Events
MMV Open
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
Pathogen Box
About the Pathogen Box
Request the Pathogen Box
Exploiting the Pathogen Box
Pathogen Box research
Supporting information
Terms & conditions
Malaria Box
About the Malaria Box
Malaria Box Research
Supporting information
Terms & conditions
Map of box orders
Follow-up guidelines
Open Source Drug Discovery
MMV Open Team
Contact us
Home
Our impact
Achievements
Achievements
First single-dose medicine to prevent the relapse of
P. vivax
approved by US FDA
Two rectal artesunate suppository products for pre-referral management of severe malaria approved
68 million courses of seasonal malaria chemoprevention delivered to countries in the Sahel in 2017
350 million treatments of Coartem®
Dispersible
delivered to over 50 countries
Pyramax® Granules added to the WHO's Model List of Essential Medicines for Children
100 million vials of Artesun® delivered to treat children with severe malaria
CANTAM study initiated
14 compounds in preclinical and clinical development
150 active partners in MMV's network, working to help defeat malaria
Over 230 Pathogen Boxes shipped
>90% of severe malaria cases now treated with injectable artesunate in preference to quinine
18,000 health-care workers trained to administer injectable artesunate for severe malaria
USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners
19 new malaria drug targets validated since 1999
MMV wins Open Data Innovation Award for work on the Malaria Box
2 ACTs developed by DND
i
and partners transitioned to MMV
More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots
Key landmarks for MMV-supported medicines
Key Achievements over MMV's first 15 years
RSS subscribe
Printer friendly